Clinical Trials
24 trialsNCT06630325 2026-04-28
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT05335941 2026-03-04
A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06630416 2026-02-24
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
Northwestern University
Phase 2 Recruiting
NCT03744793 2026-01-09
Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04198766 2025-12-18
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Phase 1/2 Active not recruiting
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT06839105 2025-05-31
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Recruiting
NCT04452214 2023-07-14
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
Cantargia AB
Phase 1 Completed
NCT00053209 2023-06-22
Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02983045 2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2 Completed
NCT03023319 2022-06-14
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Augusta University
Phase 1 Completed
NCT04173338 2022-06-14
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
Augusta University
Phase 1 Terminated
NCT02693717 2021-05-20
Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00703638 2017-11-29
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT03193788 2017-06-21
PREMIER
Asan Medical Center
Phase 3 Unknown
NCT00216099 2016-07-29
Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT01172028 2015-12-03
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
University of Arizona
Phase 1 Completed
NCT01490437 2014-09-25
PECULIAR
Asan Medical Center
Phase 2 Completed
NCT01338792 2014-03-10
Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer
University of Southern California
Phase 2 Completed
NCT00491075 2013-04-24
Pemetrexed Plus Gemcitabine in Renal Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00374868 2010-11-04
Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)
Eli Lilly and Company
Phase 1/2 Completed
NCT00101842 2006-08-29
Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT00034593 2006-07-19
A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
Eli Lilly and Company
Phase 2 Completed
NCT00035061 2006-07-19
A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium
Eli Lilly and Company
Phase 2 Completed